Fabtech Technologies Ltd delivers turnkey projects, mainly pharmaceutical manufacturing facilities, and makes about 30% of the supply in-house: process equipment, air and water systems. It operates across 62 countries and drew 78% of its revenue from MENA, GCC and ECO Zone markets as of H1 FY26. Reported revenue was 410.77 Cr in FY26, and the open order book stood at ₹900+ Cr as of June 30, 2026.[1][2][3]
Loading chart…
Our models read the latest earnings call, annual report, and financials end-to-end - then grade management, value the business, and flag the risks. Unlock all of it for this company:
The headline call - descriptive label, conviction, and the synthesis behind it.
Guidance-anchored P&L bridge - worst / average / best multiple cases.
Did management deliver on past guidance? A commitment-by-commitment scorecard.
Forensic and governance risk pointers, severity-ranked.
Solvency and earnings-quality score.
Quarter-by-quarter earnings-call briefs - what changed and why.
Sign in to see the revenue split by business segment - free.
Sign inSign in to see dividends, bonuses and splits - free.